Patient | Age (years) | Sex | Race/ ethnicity | Histology/tumor virus status | CSF disease | # Prior therapies | Antiretroviral therapy | Baseline ECOG | Baseline CD4+ T cells/μL | Baseline CD4+:CD8+ T cell ratio |
1 | 47 | M | White | Peritoneal PEL, KSHV+/EBV– | – | 2 | DOL, TAF, FTC | 1 | 132 | 0.41 |
2 | 53 | M | White | MYC rearranged GCB DLBCL, EBV– | – | 4 | DOL, TDF, FTC | 0 | 204 | 0.21 |
3 | 43 | M | Hispanic | Extracavitary PEL, KSHV+/EBV+ | – | 5 | Darunavir, ritonivir, DOL, TDF, FTC | 1 | 228 | 0.39 |
4 | 53 | M | Black | Aggressive B cell lymphoma, NOS* | – | 1 | Darunavir, cobicistat, DOL, TAF, FTC | 0 | 557 | 0.47 |
5 | 34 | F | White | Non-GCB DLBCL, EBV+ | – | 3 | DOL, TAF, FTC | 4 | 43 | 0.34 |
6 | 52 | M | Black | Extracavitary PEL†, KSHV+/EBV+ | + | 2 | DOL, abacavir, 3TC | 0 | 301 | 0.66 |
7 | 35 | M | Black | Pleural/pericardial PEL, KSHV+/EBV+ | + | 2 | DOL, TAF, FTC | 3 | 224 | 0.81 |
8 | 67 | F | Black | Non-GCB DLBCL, EBV– | + | 4 | BIC, TAF, FTC | 1 | 394 | 0.23 |
9 | 45 | F | Hispanic | PBL, EBV+ | – | 1 | BIC, TAF, FTC | 3 | 107 | 0.17 |
10 | 36 | M | White | Peritoneal PEL, KSHV+/EBV+ | + | 2 | BIC, TAF, FTC | 3 | 143 | 0.10 |
*EBV status of the tumor could not be determined in this patient.
†Patient 6 was treated for leptomeningeal PEL only. The patient’s systemic PEL was in complete remission at treatment initiation.
BIC, bictegravir; CSF, cerebrospinal fluid; DLBCL, diffuse large B cell lymphoma; DOL, dolutegravir; EBV, Epstein-Barr virus; ECOG, Eastern Cooperative Oncology Group performance score; F, cisgender female; FTC, emtricitabine; GCB, germinal center B cell; KSHV, Kaposi sarcoma herpesvirus; M, cisgender male; NOS, not otherwise specified; PBL, plasmablastic lymphoma; PEL, primary effusion lymphoma; TAF, tenofovir alafenamide fumarate; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate.